David A. Siegel Adagio Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 44,400 shares of ADGI stock, worth $146,964. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,400Holding current value
$146,964% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ADGI
# of Institutions
84Shares Held
66.8MCall Options Held
700KPut Options Held
600-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.77% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.19% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million29.1% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$14.5 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...